HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 585-589

  Tuma, Paula ^a   Pineda, Juan Antonio ^b   Labarga, Pablo ^a   Vidal, Francesc ^c   Rodriguez, Carmen ^d   Poveda, Eva ^a   Santos, Jesús ^e   Gonzalez García, Juan ^a   Sobrino, Paz ^f   Tural, Cristina ^g   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d Sandoval Health Centre   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f CARLOS III INSTITUTE OF HEALTH   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; SEX RATIO; SEXUAL BEHAVIOR; SPAIN; STRUCTURAL GENE; VIRUS CHARACTERIZATION; VIRUS DIAGNOSIS; VIRUS GENE; VIRUS LOAD;

ADULT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN;

EID: 79959482415     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1778     Document Type: Article

References (27)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 Suppl 1:S6-S9. (Pubitemid 43053865)
2. Lok AS, McMahon B. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
3. Vallejo F, Toro C, de la Fuente L, et al. Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs. J Subst Abuse Treat 2008; 34:398-406. (Pubitemid 351622097)
4. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137:1593-1608.
5. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61:766-768. (Pubitemid 351426057)
6. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder R, Torresi J. Global control of HBV: does treatment-induced antigenic change affect immunization? Bull World Health Organ 2010; 88:66-73.
7. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133. (Pubitemid 34062194)
8. Ludwig A, Goebel T, Adams O, et al. Primary resistance mutations against nucleos(t)ide analogues in treatment naïve patients with HBV infection. American Association for the Study of Liver Diseases. 31 October - 4 November 2008, San Francisco, CA, USA. Abstract 884.
9. Fung S, Mazulli T, El-Kashab M, Sherman M, Popovic V. Lamivudine-resistant mutation among treatment-naive hepatitis B patients is common and may be associated with treatment failure. American Association for the Study of Liver Diseases. 31 October - 4 November 2008, San Francisco, CA, USA. Abstract 888.
10. Xu Z, Liu Y, Xu T, et al. Acute hepatitis B infection associated with drug resistant hepatitis B virus. J Clin Virol 2010; 48:270-274.
11. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999; 30:1302-1306 (Pubitemid 29510871)
12. Caro-Murillo AM, Castilla J, Perez-Hoyos S, et al. Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results. Enferm Infecc Microbiol Clin 2007; 25:23-31. (Pubitemid 46232687)
13. García-Merino I, de Las Cuevas N, Jiménez JL, et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009; 6:27.
14. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870. (Pubitemid 43731568)
15. Max-Planck-Institut Informatik. Geno2pheno [hbv]. (Updated 8 January 2011. Accessed 8 January 2011.) Available from http://hbv.bioinf.mpi-inf.mpg.de/ index.php
16. Servant-Delmas A, Mercier M, El Ghouzzi M, et al. National survey of HBV polymorphisms in asymptomatic HBV blood donors from 1999 to 2007 in France. Transfusion 2010; 50:2607-2618.
17. Rodriguez-Frias F, Jardi R, Schaper M, et al. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther 2008; 13:991-999.
18. Bottecchia M, Madejon A, Sheldon J, Garcia-Samaniego J, Barreiro P, Soriano V. Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. J Antimicrob Chemother 2008; 62:626-627.
19. Sloan RD, Strang A, Ramsay M, Teo C. Genotyping of acute HBV isolates from England, 1997-2001. J Clin Virol 2009; 44:157-160.
20. Soriano V, Mocroft A, Peters L, et al. Predictors of HBV genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 2010; 65:548-555
21. Treviño A, Soriano V, Madejon A, et al. Transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. AIDS Res Hum Retroviruses 2009; 25:1273-1276.
22. Wongprasit P, Manosuthe M, Kiertiburanakul S, Sungkanuparh S. Hepatitis B virus drug resistance in HIV-infected patients taking lamivudine-containing antiretroviral therapy. AIDS Patient Care STDS 2010; 24:205-209.
23. Margeridon-Thermet S, Shulman N, Ahmed A, et al. Ultra-deep pyrosequencing of HBV quasispecies from nucleoside and nucleotide reverse transcriptase inhibitor (NRTI)- treated patients and NRTI-naïve patients. J Infect Dis 2009; 199:1275-1285.
24. Hirsch MS, Gunthard H, Schapiro J, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
25. Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis 2008; 47:1486-1489
26. Hoffmann CJ, Charalambous S, Martin D, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479-1485.
27. Thio CL, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev 2007; 9:40-53. (Pubitemid 46730282)